Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases

Warren, Nicola; O’Gorman, Cullen; Lehn, Alexander; Siskind, Dan

doi:10.1136/jnnp-2017-315985

Cited by 136 publications

(85 citation statements)

References 38 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although nearly all the patients showed some improvement after phased reduction in dopaminergic treatment, nearly half of them remained symptomatic until death. This is a similar remission rate to a systematic review on DDS and higher than a long‐term retrospective study …”

Section: Discussionsupporting

confidence: 81%

“…The fact that dyskinesias tended to predate DDS suggests that PD patients at risk who develop dyskinesias should be carefully screened for DDS. Only around one third of the patients with DDS had other ICBs, which is lower than in a recent systematic review …”

Section: Discussioncontrasting

confidence: 64%

“…l ‐dopa is believed to be the main risk factor for the development of DDS . DAs were used as an add‐on therapy by more than 50% of the patients with DDS, in line with a recent review …”

Section: Discussionsupporting

confidence: 53%

“…Patients with DDS had earlier disease onset and longer disease duration, which probably reflects the predominance of younger patients . However, DDS patients died at an earlier age than patients without DDS, probably reflecting the earlier age of onset.…”

Section: Discussionmentioning

confidence: 93%

See 3 more Smart Citations

The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study

Barbosa

Djamshidian

Lees

et al. 2018

Movement Disord Clin Pract

View full text Add to dashboard Cite

Introduction We have performed a retrospective analysis of the frequency and relation to treatment of dopamine dysregulation syndrome (DDS) using the Queen Square Brain Bank (QSBB) database. Methods A search of the QSBB database for consecutive cases donated between 2005 and 2016 with a pathological diagnosis of Parkinson's disease was performed. Results DDS was present in 8.8% of cases, was more prevalent in males, and was associated with younger age of onset, longer disease duration, and more dopa‐induced dyskinesias. Treatment approaches for DDS included: reduction of levodopa, reduction/cessation of dopamine agonist (DA), and initiation of infusion therapies. DDS had completely resolved in just over half the patients. DA peak l‐dopa equivalent daily dose (LEDD) was higher in patients who failed to achieve remission. Conclusion This is the first study to provide data on the course of DDS until death. Treatment strategies consisted mainly of reduction of dopaminergic treatment, and, despite the majority of patients showing some improvement, half remained symptomatic. Successful treatment was associated with a lower l‐dopa dosage at death.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussioncontrasting

confidence: 64%

“…l ‐dopa is believed to be the main risk factor for the development of DDS . DAs were used as an add‐on therapy by more than 50% of the patients with DDS, in line with a recent review …”

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 93%

See 2 more Smart Citations

The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study

Barbosa

Djamshidian

Lees

et al. 2018

Movement Disord Clin Pract

View full text Add to dashboard Cite

show abstract

“…Patients suffering from DDS display an altered perception of their motor status, feeling relieved from motor symptoms only when they are highly dyskinetic (Giovannoni et al 2000;Lawrence et al 2003). Over 90% of PD patients suffering from DDS indeed display drug seeking behavior and escalation of L-dopa intake (Warren et al 2017). They rapidly consume the amount of prescribed DRT, and then they engage in pathological drug seeking and hoarding to maintain adequate drug supply (Warren et al 2017).…”

Section: Addiction To Da Replacement Therapy Medications In Parkinsonmentioning

confidence: 99%

Dopamine and addiction: what have we learned from 40 years of research

et al. 2018

View full text Add to dashboard Cite

Among the neurotransmitters involved in addiction, dopamine (DA) is clearly the best known. The critical role of DA in addiction is supported by converging evidence that has been accumulated in the last forty years. In the present review, firstly we describe the dopaminergic system in terms of connectivity, functioning and involvement in reward processes. Secondly, we describe the functional, structural, and molecular changes induced by drugs within the DA system in terms of neuronal activity, synaptic plasticity and transcriptional and molecular adaptations. Thirdly, we describe how genetic mouse models have helped characterizing the role of DA in addiction. Fourthly, we describe the involvement of the DA system in the vulnerability to addiction and the interesting case of addiction DA replacement therapy in Parkinson's disease. Finally, we describe how the DA system has been targeted to treat patients suffering from addiction and the result obtained in clinical settings and we discuss how these different lines of evidence have been instrumental in shaping our understanding of the physiopathology of drug addiction.

show abstract

Pharmacological and non-pharmacological treatments for impulsive-compulsive behaviors in Parkinson's disease

Mantovani

Martini

Tamburin

2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases

Abstract: Given the functional impairment, medical and psychiatric consequences and the difficulties of treatment, early identification of DDS should be a priority.

Cited by 136 publications

References 38 publications

The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study

The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study

Dopamine and addiction: what have we learned from 40 years of research

Pharmacological and non-pharmacological treatments for impulsive-compulsive behaviors in Parkinson's disease

Contact Info

Product

Resources

About